Molecule

S1384 

Research Area: Immunology
Biological Activity:
Mizoribine (Bredinin) is an imidazole nucleoside and an immunosuppressive agent with an IC50 of approximately 100 μM. The immunosuppressive effect of mizoribine (Bredinin) has been reported to be due to the inhibition of DNA synthesis in the S phase of the cell cycle. Because of its relative lack of toxicity, during the past decade mizoribine (Bredinin) has been frequently used instead of azathioprine as a component of immunosuppressive drug regimens. Mizoribine (Bredinin) is being used to treat renal transplantation patients, IgA nephropathy, lupus erythematosus, and childhood nephrotic syndrome (NS), and some recent studies have assessed the efficacy of oral mizoribine (Bredinin) pulse therapy for severe lupus nephritis, steroid-resistant NS, and frequently relapsing-steroid-dependent NS. [1][2][3]

M3047 

Biochem/physiol Actions
Mizoribine is an imidazole nucleoside possessing strong immunosuppressive properties. Selectively blocks T-cell proliferation response to mitogenic and allo-antigenic stimulation. Mizoribine blocks the movement of T cells from G to S phase. In addition, it significantly decreases the number of B cells at the S, G, and M phases. Mizoribine inhibits de novo synthesis of nucleotides by inhibition of inosine monophosphate dehydrogenase. The resulting nucleotide depletion inhibits DNA synthesis.